Factor II
Code
EER037032
CE MarkEER037032
Tests

32 Tests - G20210A Mut

Available for QiaSymphony SP/AP - Ref. EER028032QS

Factor II

DuplicαRealTime Mix & Match FACTOR II G20210A Kit is an in vitro diagnostic test for the detection of the nucleotide substitution G20210A (allelic variant g.46739505G>A) in the blood coagulation Factor II gene, by Real-Time PCR.

 

Overview

Prothrombin G20210A (also the Prothrombin 20210 mutation, the Factor II mutation, or the Prothrombin mutation) is a genetic variant that approximately doubles or triples the risk of forming blood clots in the veins. The variant is commonly associated with the Venous Thromboembolism (VTE) disease, which includes both deep vein thrombosis and pulmonary embolism.

About 2 to 3% of Caucasians carry the Prothrombin G20210A variant, and it confers a 2 to 3 fold higher risk of VTE. Deficiencies in the anticoagulants Protein C and Protein S give a higher risk (5 to 10 fold). Behind non-O blood type and Factor V Leiden, Prothrombin G20210A is one of the most common genetic risk factors for VTE. The variant causes elevated plasma Prothrombin levels (hyperprothrombinemia), possibly due to increased pre-mRNA stability.

Prothrombin is the precursor of Thrombin, which plays a key role in causing blood coagulation. G20210A can thus contribute to a state of hypercoagulability, but not particularly with arterial thrombosis. Recently it has been showed a 1.3 fold increased risk only for coronary disease. Heterozygous carriers who take oral contraceptives are at a 15 fold increased risk of VTE, while carriers also heterozygous for Factor V Leiden have an approximate 20 fold higher risk and it seems to be increased when FII G20210A transition is associated with the Factor V Leiden mutation.

In a recommendation statement on VTE, genetic testing for G20210A in adults that developed unprovoked VTE was disadvised, as was testing in asymptomatic family members related to G20210A carriers who developed VTE. In those who develop VTE, the results of thrombophilia tests (wherein the variant can be detected) rarely play a role in the length of treatment.

Targets:

  • Nucleotide  G20210A substitution of the blood coagulation Factor II gene
  • Internal Control (IC)

Diagnostic samples:

  •  Peripheral whole blood samples collected in EDTA

DNA Extraction:

  • Compatible with the most common DNA Extraction and Purification Systems

Real-Time PCR instruments:

  • Compatible with the most common Real-Time PCR Systems

Clonit DuplicaRealTime Mix & Match kits belong to the CardioVascular Diseases panel – CVD Panel. Their protocols can be automated on QiaSymphony SP/AS (Qiagen)  and share the same thermal profile.